The latest venture of Chicago-based entrepreneur Eric Lefkofsky is Tempus, a project that will revolutionize the future of healthcare. It’s an ambitious undertaking, but one with huge potential to improve lives and change history. This article will provide you with information about Eric Lefkofsky and Tempus – who it targets, how it works, what its goals are – so that you can decide for yourself whether or not this is something worth investing in.
Eric Lefkofsky is an entrepreneur best known for founding Lightbank. He’s also the founder of Tempus, a company that focuses on developing new drugs to combat the spread of antibiotic-resistant bacteria. The world is facing what has been called “the end of antibiotics”, and with only one more new class coming in 2027, we must find solutions now. So far, there are five treatments in clinical trials which will be tested by 2020 to see if they can help stop this trend.
Tempus is working on five as well and hopes to have them submitted for approval by 2022. The FDA has already approved two of Tempus’s treatments for urinary tract infections and another for a certain type of E-coli infection. As Eric Lefkofsky states, the company expects their first submission will be successful too, which makes sense given that the drugs they’ve developed so far are better than anything else we currently have available.
And it doesn’t stop there: Eric Lefkofsky wants to take things even further with his newest company focusing solely on antibiotics! Tempus is just getting started, but this ambitious project could lead us into a future where all our medical issues can be solved simply by visiting your local pharmacy rather than making an appointment at the doctor’s office.
